Patient-Reported Outcomes in the Treatment of Schizophrenia

This study has been completed.

First Received: September 12, 2005 Last Updated: September 6, 2007 History of Changes

Sponsored by:	Solvay Pharmaceuticals
Information provided by:	Solvay Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00230828

Purpose

Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Condition	Intervention	Phase
Schizophrenia	Drug: bifeprunox	Phase III

MedlinePlus related topics: Schizophrenia

Drug Information available for: Bifeprunox Bifeprunox mesylate

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Patient-Reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials

Further study details as provided by Solvay Pharmaceuticals:

Study Start Date:

May 2005

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230828

Sponsors and Collaborators

Solvay Pharmaceuticals

Investigators

Study Director:

Global Clinical Director Solvay

Solvay Pharmaceuticals

More Information

No publications provided

Study ID Numbers:	S154.3.005
Study First Received:	September 12, 2005
Last Updated:	September 6, 2007
ClinicalTrials.gov Identifier:	NCT00230828 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Schizophrenia
Mental Disorders
Olanzapine
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Schizophrenia
Mental Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on May 07, 2009